Sense of smell is our most rapid warning system
The ability to detect and react to the smell of a potential threat is a precondition of our and other mammals’ survival. Using a novel technique, researchers at… read more.
The ability to detect and react to the smell of a potential threat is a precondition of our and other mammals’ survival. Using a novel technique, researchers at… read more.
Oyster Point Pharma, Inc. announced that the FDA has approved Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye… read more.
Impel NeuroPharma, Inc. announced that the FDA approved Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in… read more.
Merck Inc., announced the FDA has approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes… read more.
Journal of Clinical Investigation The discovery that multiciliated cells in the nasal epithelium are the first cells to be targeted in early COVID-19 infection might provide the rationale… read more.
Edwards Lifesciences announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra… read more.
Cochlear implants are a groundbreaking technology that has changed the lives of many people living with severe to profound hearing loss.
Novartis has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Xolair (omalizumab) as… read more.
Through an agreement with National Health Service (NHS) and Sobi,( Swedish Orphan Biovitrium) people living with haemophilia A in the United Kingdom will have increased access to Elocta… read more.
GlaxoSmithKline announced positive results from the pivotal phase III SYNAPSE study of Nucala (mepolizumab) in patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). This is the first… read more.
Regeneron Pharmaceuticals announced that detailed Phase III ELIPSE HoFH trial results of REGN 1500 (evinacumab) in patients with homozygous familial hypercholesterolemia (HoFH). The data showed the trial met… read more.
Includes education and counselling component for caregivers American Academy of Otolaryngology – Head and Neck Surgery
Advertisment